Journal Watch · Genome Biology · 2026
FIRST-seq: a nanopore-based cDNA sequencing platform for RNA modification and structure profiling.
FIRST-seq offers a versatile platform for profiling chemical-induced and natural RNA modifications using long-read sequencing.
TL;DR
FIRST-seq offers a versatile platform for profiling chemical-induced and natural RNA modifications using long-read sequencing.
Key findings
- FIRST-seq offers a versatile platform for profiling chemical-induced and natural RNA modifications using long-read sequencing.
What they did
Benchmarking multiple RT enzymes and buffers identified conditions that reduce premature termination and enhance error detection. Coupled with DMS probing, FIRST-seq accurately detects m1A and m3C at unpaired sites, recapitulating known RNA structures in vitro and in vivo.
Full abstract (original)
Background: RNA modifications induce reverse transcription (RT) errors in an enzyme- and context-dependent manner, enabling transcriptome-wide mapping and RNA structure probing. We present FIRST-seq, a flexible, cost-effective nanopore cDNA method that avoids second-strand synthesis and PCR, making it compatible with any RT enzyme and enabling single-nucleotide resolution RT signature analysis.
What they did: Benchmarking multiple RT enzymes and buffers identified conditions that reduce premature termination and enhance error detection. Coupled with DMS probing, FIRST-seq accurately detects m1A and m3C at unpaired sites, recapitulating known RNA structures in vitro and in vivo.
Results & conclusions: FIRST-seq offers a versatile platform for profiling chemical-induced and natural RNA modifications using long-read sequencing.
Abstract © the authors / Genome Biology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1186/s13059-026-04115-w · PubMed 42218558.
Why it matters for pharma & biotech
- Relevant to Biology & Life Sciences teams tracking Genome Biology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Genome Biology study find?
FIRST-seq offers a versatile platform for profiling chemical-induced and natural RNA modifications using long-read sequencing.
What type of study is this?
It is a in-vitro / cell study, published in Genome Biology in 2026. Benchmarking multiple RT enzymes and buffers identified conditions that reduce premature termination and enhance error detection.
Where can I read the original paper?
The original is at the publisher via DOI 10.1186/s13059-026-04115-w. PubMed ID: 42218558. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/first-seq-a-nanopore-based-cdna-sequencing-platform-for-rna-modification-04115w/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides